Gamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 Million
Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, today announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash.
Mirus Bio Named a Top Workplace by the Wisconsin State Journal
Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces. This award is based solely on employee feedback collected from a survey administered by an external organization.
ASGCT 2024
Mirus Bio will be exhibiting at ASGCT 2024 in Baltimore, Maryland at Booth #2017.
Mirus Bio Receives ISO 13485:2016 Certification
Mirus Bio Receives ISO 13485:2016 Certification Completion of this comprehensive certification process underscores the quality of the processes used to support the company’s GMP product portfolio MADISON, Wis., January 31, 2024 — Mirus Bio, a life sciences company developing innovative solutions for nucleic acid delivery to support cell and gene therapy production, biopharmaceutical manufacturing, and research applications, today […]
VirusGEN® and RoosterGEM™, a match made for GMP mRNA transfection
Here we highlight some of the exciting results from Mirus’ ongoing collaboration with RoosterBio. Earlier this year, RoosterBio presented a poster at ASGCT and ISCT which showcased using TransIT-VirusGEN® for high-efficiency transfection of mRNA into human mesenchymal stromal cells (hMSCs) cultured in RoosterGEM™ medium. Both VirusGEN® and RoosterGEM™ have GMP formulations available, which allows for rapid implementation into clinical manufacturing processes that require highly qualified reagents.
Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines
The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines Cambridge, Mass. (January 31, 2023) ‒ Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus […]
Mirus Bio Launches RevIT™ AAV Enhancer
Delivers 2-4x increase in AAV titers across many serotypes, cell lines, growth media, and transfection reagents Significantly reduces production costs and doubles the doses that can be produced in a single bioreactor run MADISON, Wis., Aug. 3, 2023 /PRNewswire/ — Mirus Bio, a life sciences company developing innovative solutions for nucleic acid delivery to support cell and gene […]
Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines
The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines Cambridge, Mass. (January 31, 2023) ‒ Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus […]
Gamma Biosciences Launches Initiative Through Mirus Bio to Develop Lipid-Polymer Nanocomplexes for In Vivo mRNA Delivery
Menlo Park, CA and Madison, WI (Mar 22, 2022) ‒ Gamma Biosciences, a global life sciences company serving the advanced therapy market, today announced an initiative through its subsidiary Mirus Bio, a leader in nucleic acid delivery technology, to develop novel, highly active lipid-polymer nanocomplexes for therapeutic mRNA delivery in vivo. The newly created initiative within Mirus […]
Mirus Bio Expandes TransIT-VirusGEN® SELECT Portfolio with the Addition of Transfection Kits to Increase Titers in Cell and Gene Therapy Manufacturing
Madison, Wis. (Feb 24, 2022) ‒ Mirus Bio, a leading provider of delivery solutions within Gamma Biosciences, today launched TransIT-VirusGEN® SELECT Transfection Kits for large-scale viral vector production for cell and gene therapy applications. The kits support pre-clinical and process development activities and consist of the TransIT-VirusGEN® Transfection Reagent, complex formation solution and enhancer. The full kits are […]